Keywords: vivus, evamist, nda, accepted, fda, drugmaker, says
Vivus' EvaMist NDA accepted by US FDA
Article | 18 December 2006
US drugmaker Vivus says that its New Drug Application for EvaMist, its novel, once-a-day, proprietary, first-in-class, transdermal estradiol spray, was ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
